Abstract:Persistent pulmonary hypertension of the newborn (PPHN) is a medical emergency in the neonatal period, which occurs due to failure of normal postnatal transition of fetal circulation. Despite availability of numerous treatment modalities, associated mortality and morbidity remain high. Therefore, awareness of predisposing conditions, and early diagnosis and management may help improving outcome in PPHN. To provide an overview of anatomic and functional anomalies of PPHN, and available treatment options with special focus on recent advances in the diagnosis and management of this potentially lethal illness. MEDLINE, EMBASE, The Cochrane Library, and Google Scholar databases were searched (inception until Nov-2012) using terms “ persistent pulmonary hypertension of newborn ” , “ hypoxemic respiratory failure ” , “ nitric oxide ” , “ sildenafil ” , “ milrinone ” and “ prostacyclin ” without any language restriction. www.clinicaltrials.gov website was searched for relevant ongoing trials. Additionally, manual review of article bibliographies was done for potentially relevant studies. Strategies for the management of PPHN are undergoing metamorphosis. Gentle ventilation and high-frequency ventilation have replaced prior hyperventilation strategy. Currently, iNO is the only FDA-approved selective pulmonary vasodilator for infants with hypoxemic respiratory failure / PPHN; however, it has poor / no response in upto 30% cases. Recent studies have provided evidences for the use of other therapeutic agents such as PDE-inhibitors, magnesium sulphate and prostacyclin analogues. Finally, recent laboratory studies have demonstrated the role of oxidant stress as well as potential use of free radical scavengers for example, superoxide dismutase and catalase in the management of PPHN. Assisted ventilation and pharmacologic manipulation are the mainstays of treatment of PPHN. Limited availability of the gold standard treatment option namely iNO, especially in resource-limited countries, leads to increasing use of alternative therapeutic options such as PDE-inhibitors (sildenafil and milrinone). However, as any single therapy can not be labelled as a magic bullet for PPHN, further clinical trials are required to demonstrate the efficacy and safety of available therapeutic options as well as to develop newer strategies targeted to the underlying pathophysiology. doi: http://dx.doi.org/10.4021/ijcp79w

Pathophysiologic principles relevant for therapeutic procedures in persistent pulmonary hypertension of the newborn

Pathophysiologic Principles Relevant for Therapeutic Procedures in Persistent Pulmonary Hypertension of the Newborn

The Progress in the Treatment of Persistent Pulmonary Hypertension in Neonatal

Pharmacologic therapy of persistent pulmonary hypertension of the newborn

Persistent pulmonary hypertension of the newborn: Advances in diagnosis and treatment

Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn

Pathophysiology, Management, and Outcome of Persistent Pulmonary Hypertension of the Newborn: A Clinical Review

Persistent pulmonary hypertension of the newborn: therapeutical approach.

Recent Advances in the Pathogenesis and Treatment of Persistent Pulmonary Hypertension of the Newborn

Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches

Pathophysiology of persistent pulmonary hypertension of the newborn: Impact of the perinatal environment

Current Pharmaceutical Strategies in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN): A Comprehensive Review of Therapeutic Agents

Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment

Persistent Pulmonary Hypertension of the Newborn: Recent Advances in the Management

Diagnosis and management of persistent pulmonary hypertension of the newborn

Molecular physiopathogenetic mechanisms and development of new potential therapeutic strategies in persistent pulmonary hypertension of the newborn

Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn

Pulmonary hypertension in the newborn- etiology and pathogenesis

Pathophysiology and Management of Persistent Pulmonary Hypertension of the Newborn